• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AstraZeneca - Articles and news items

Lynparza Phase III data demonstrates progression-free survival in ovarian cancer

Industry news / 17 March 2017 / Niamh Marriott, Junior Editor

AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95% CI 0.22 to 0.41; P<0.0001; […]

AstraZeneca Phase III breast cancer trial met primary endpoint

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

AstraZeneca announced positive results from its Phase III trial comparing Lynparza to chemotherapy, to treat HER2-negative metastatic breast cancer…

astrazeneca

2017 pipelines: AstraZeneca – another challenging year

Blog, Z Homepage promo / 8 February 2017 / Brian White and Paul Taylor, Healthcare analysts, Cantor Fitzgerald Europe

Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold

Industry news / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly….

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

NICE recommends first drug for the Cancer Drugs Fund

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

Osimertinib is the first new cancer drug to be introduced into the NHS under a Cancer Drugs Fund managed access agreement…

MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

Pfizer to acquire AstraZeneca’s anti-infective business

Industry news / 24 August 2016 / Pfizer

The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL…

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.

NICE recommends thousands to receive £2-a-day anti-clotting drug

Industry news / 15 August 2016 / National Institute for Health and Care Excellence (NICE)

A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke…

Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug

Industry news / 9 August 2016 / AstraZeneca

The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +